SB 341
10 links on this map: who funds them, what they touched, and who lobbied on it. Select anyone to move the map to them.
Start with
and connect to
Browse all held record sources
Zoom to read. Drag to explore. Select a connection.
SB 341
Pharmaceuticals: adverse drug reactions: Drug Safety and Effectiveness Program
California · Introduced
Every link on this map
The same connections as a table, with the reason each one is here.
| Mark DeSaulnier | Sponsors | Mark DeSaulnier sponsored SB 341. | None |
| Novartis Services, Inc | Lobbied on it | Novartis Services, Inc named SB 341 in 7 lobbying reports. | 7 reports |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Lobbied on it | Boehringer Ingelheim Pharmaceuticals, Inc. named SB 341 in 5 lobbying reports. | 5 reports |
| Amylin Pharmaceuticals, Inc. | Lobbied on it | Amylin Pharmaceuticals, Inc. named SB 341 in 4 lobbying reports. | 4 reports |
| GSK | Lobbied on it | GSK named SB 341 in 4 lobbying reports. | 4 reports |
| Millennium Pharmaceuticals Inc. | Lobbied on it | Millennium Pharmaceuticals Inc. named SB 341 in 4 lobbying reports. | 4 reports |
| Sunovion Pharmaceuticals Inc. | Lobbied on it | Sunovion Pharmaceuticals Inc. named SB 341 in 4 lobbying reports. | 4 reports |
| Amgen | Lobbied on it | Amgen named SB 341 in 3 lobbying reports. | 3 reports |
| Astrazeneca Pharmaceuticals, LP | Lobbied on it | Astrazeneca Pharmaceuticals, LP named SB 341 in 3 lobbying reports. | 3 reports |
| Pharmaceuticals: adverse drug reactions: Drug Safety and Effectiveness Program. | Source records | SB 341 has an explicit source reference to Pharmaceuticals: adverse drug reactions: Drug Safety and Effectiveness Program.. | None |
In the news
Reporting about the selected subject. Articles are context and do not establish a connection on this map.
Loading coverage…